User profiles for K. L. Lanctot

Krista Lanctot

Sunnybrook Research Institute, University of Toronto
Verified email at sunnybrook.ca
Cited by 32113

Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits

J Glass, KL Lanctôt, N Herrmann, BA Sproule… - Bmj, 2005 - bmj.com
Objectives To quantify and compare potential benefits (subjective reports of sleep variables)
and risks (adverse events and morning-after psychomotor impairment) of short term …

Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis

KL Lanctôt, N Herrmann, KK Yau, LR Khan, BA Liu… - Cmaj, 2003 - Can Med Assoc
Lanctôt and Herrmann conceived and designed the study and contributed substantially to …
Lanctôt received research honoraria and/or speaker fees and/or travel assistance from Pfizer, …

Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis

…, N Herrmann, CL Raison, BJ Miller, KL Lanctot… - Molecular …, 2018 - Springer
Mounting evidence suggests that aberrations in immune-inflammatory pathways contribute
to the pathophysiology of major depressive disorder (MDD), and individuals with MDD may …

A meta-analysis of cytokines in major depression

…, W Swardfager, H Liu, L Sham, EK Reim, KL Lanctôt - Biological …, 2010 - Elsevier
BACKGROUND: Major depression occurs in 4.4% to 20% of the general population. Studies
suggest that major depression is accompanied by immune dysregulation and activation of …

Peripheral cytokine and chemokine alterations in depression: a meta‐analysis of 82 studies

…, CL Raison, BJ Miller, KL Lanctôt… - Acta Psychiatrica …, 2017 - Wiley Online Library
Objective To conduct a systematic review and meta‐analysis of studies that measured cytokine
and chemokine levels in individuals with major depressive disorder ( MDD ) compared to …

Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future

…, J Bell, J Evans, M Lee, A Porsteinsson, KL Lanctôt… - Alzheimer's & …, 2013 - Elsevier
Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are widespread and disabling.
This has been known since Dr. Alois Alzheimer's first case, Frau Auguste D., presented …

Peripheral inflammatory markers in Alzheimer's disease: a systematic review and meta-analysis of 175 studies

KSP Lai, CS Liu, A Rau, KL Lanctôt… - Journal of Neurology …, 2017 - jnnp.bmj.com
Objectives Increasing evidence suggests that inflammation is involved in Alzheimer’s disease
(AD) pathology. This study quantitatively summarised the data on peripheral inflammatory …

[HTML][HTML] Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms

KL Lanctôt, J Amatniek, S Ancoli-Israel… - Alzheimer's & Dementia …, 2017 - Elsevier
Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing
substantial distress for both people with dementia and their caregivers, and contributing to early …

[HTML][HTML] Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: update and areas of immediate need

…, LA Johnson, R Jutten, K Kilborn, KL Lanctôt… - Alzheimer's & …, 2019 - Elsevier
Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging
population and society as a whole. With the numbers of people with ADRDs predicted to rise …

[HTML][HTML] The Mild Behavioral Impairment Checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations

…, N Herrmann, J Kanji, KL Lanctôt… - Journal of Alzheimer's …, 2017 - ncbi.nlm.nih.gov
Background Mild Behavioral Impairment (MBI) is a construct that describes the emergence
at≥ 50 years of age of sustained and impactful neuropsychiatric symptoms (NPS), as a …